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Abstract
Objectives: Doctors perceive the interactions with phar-
maceutical representatives as professionally appropriate.
However, studies have shown that the interaction is
associated with less rational prescribing of medications.
No previous study has assessed doctors’ opinions of the
presentation of pharmaceutical representatives and the
quality of claims provided to the doctors in Australia and
Malaysia. The aim of this study was to compare the
opinions of Australian and Malaysian doctors of sales
explanations and quality of claims provided by the
pharmaceutical representatives.
Methods: We recruited samples of primary care doctors
in Australia and Malaysia to evaluate pharmaceutical
sales visits. After a visit, doctors were asked to fill out a
questionnaire on the main product and claims discussed
during the visit. Descriptive statistics were employed, and
Chi-square analysis and clustered linear regression were
used to assess differences between doctors from both
countries.y. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2015.03.002
N. Othman et al.472Results: The majority of doctors reported that the pre-
sentations were convincing as well as likely to change
their prescribing habits and improved their knowledge.
The majority of marketing claims recorded by doctors in
Australia and Malaysia were classified as vague claims.
Approximately one-third of the claims were unambigu-
ous (Australia 31% and Malaysia 33%). In a majority of
the presentations (Australia, 65%, Malaysia, 84%),
doctors indicated that the primary claims by the phar-
maceutical representatives were entirely or nearly
accurate.
Conclusions: Doctors in Australia and Malaysia held
generally positive views of the presentations of pharma-
ceutical representatives, although the information being
presented varied.
Keywords: Australia; Claims; Malaysia; Pharmaceutical
representatives; Promotion
 2015 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Pharmaceutical companies employ pharmaceutical repre-
sentatives to provide information on their medicines to doc-
tors. In France, pharmaceutical companies spent
approximately V3300 million (USD$ 4368 million) on the
activities of pharmaceutical representatives, which is equal to
75%of the total promotional budget.1 InAustralia,more than
70% of general practitioners regularly meet pharmaceutical
representatives in their daily practice.2 Doctors have
reported that their interactions with pharmaceutical
representatives are professionally appropriate.2,3 However,
studies have shown that the reliance of doctors on
commercial information may lead to less rational prescribing
of medications.4
Evidence has shown that doctors have a wide range of
opinions regarding the presentation of pharmaceutical rep-
resentatives.5e9 Some studies have reported that doctors’
views toward the presentation and information provided by
pharmaceutical representatives were primarily negative.5,6
In 2010, a study examined 58 American doctors’ views of
and interactions with representatives of the pharmaceutical
industry.5 Doctors had partially negative views of the
educational and informational value of the activities. In
2012, among the 608 doctors surveyed in Libya, 56%
(n ¼ 342) indicated that verbal information was not always
consistent with the written information that was provided.6
In contrast, some studies suggest that amajority of doctors
have positive views toward the presentations of pharmaceu-
tical representatives.7e9 In 2006, a survey of a nationally
representative random sample of 2608 doctors in the US
indicated that 74% of doctors judged the information
provided by pharmaceutical representatives as somewhat or
very useful.7In 2003, 107 doctors in the United Kingdom (UK)
participated in a qualitative survey to examine the reasons for
receiving visits from pharmaceutical representatives.8 Most
doctors meet with pharmaceutical representatives because
they quickly provide new drug information. Doctors viewed
pharmaceutical representatives as legitimate information
providers.8
Concerns have been raised regarding the quality of in-
formation provided by pharmaceutical representatives. A
recent multi-country study involving Canada, France and
the United States (US) determined that pharmaceutical
representatives commonly presented positive information
regarding their products but often omitted negative aspects,
such as side effects, contraindications and interactions.10 The
information regarding the imbalance of medicines provided
by pharmaceutical representatives in Australia and
Malaysia was also noted in a subset of this survey, which
was recently reported.11
A previous discussion on the influence of pharmaceutical
representatives has also focused on the provision of samples,
gifts and invitations to company-sponsored programs to
doctors.12e14 These gifts and samples have the potential to
bias the judgement of doctors and are associated with
increased prescribing costs and increased prescribing of new
medicines.15e17 In addition, gifts may lead to favourable
attitudes toward pharmaceutical presentations.18,19
In Australia and Malaysia, pharmaceutical promotion of
prescription medicines is self-regulated by pharmaceutical
companies.20,21 Medicines Australia and the Pharmaceutical
Association of Malaysia (PhAMA) codes of conduct
are designed to complement the requirements dictated
by government legislation.20,21 The pharmaceutical
company codes provide standards for the ethical
promotion of pharmaceutical products to healthcare
professionals.20,21
MedicinesAustralia has allocated resources formonitoring
promotional activities and publishes comprehensive reports of
all code breaches and sanctions imposed as well as details of
industry sponsored educational events on its website.20,21 In
addition, pharmaceutical representatives are required to
participate in an educational program that is endorsed by
Medicines Australia.20 To the best of our knowledge, no
study has assessed and compared doctors’ opinions of the
presentations of pharmaceutical representative in Australia
and Malaysia, which are examples of developed and
emerging countries with different resources to control
promotional activities.
This study aimed to determine the views of Australian and
Malaysian doctors of sales presentations and the quality of
claims provided by pharmaceutical representatives. The ob-
jectives were as follows:1. To examine the opinions of Australian and Malaysian
doctors on the persuasiveness of the presentation, the
quality of information presented, the likelihood that they
would start prescribing the pharmaceutical representa-
tives’ products or prescribe them more frequently and the
value of the visit in terms of knowledge gained.
2. To classify the types of marketing claims made about
benefits or harms including unambiguous, vague, emotive
and non-clinical claims.
Doctors’ views on pharmaceutical representatives’ claims 4733. To examine the provision of samples, gifts and invitations
to company-sponsored programmes by pharmaceutical
representatives to doctors.Materials and Methods
Ethics statement
This study was approved by the Human Research Ethics
Committee of the University of South Australia, Universiti
Sains Malaysia and Universiti Kebangsaan Malaysia.
Study design
We recruited samples of primary care doctors in Australia
and Malaysia to evaluate pharmaceutical sales visits. This
study was conducted from August 2007 to April 2009 (20
months). Doctors who met with pharmaceutical represen-
tatives in their regular practice and were practicing at least
25 h per week during the study period were invited to
participate. Doctors who agreed to join the study were
required to fill out a written consent prior to participation in
the research.
Recruitments of general practitioners
The doctors were asked to monitor four to ten encounters
with pharmaceutical representatives. A doctor-
pharmaceutical representative encounter was defined as
one meeting between doctor(s) and pharmaceutical repre-
sentative(s) that happened at the doctor’s office. The meeting
was based on an appointment and had to be longer than one
minute. “Corridor” meetings with pharmaceutical represen-
tatives were not considered suitable for this study.
Australia
Two mechanisms were employed to recruit doctors in
Australia.
1. Eleven divisions of general practices contacted general
practitioners on our behalf. These organisations are
members of the network of the Australian Divisions of
General Practice and funded by the Australian Govern-
ment Department of Health and Ageing.22
2. Doctors who were Healthy Skepticism23 subscribers were
invited to participate in the study and could nominate two
doctors who would also be willing to participate. Healthy
Skepticism is an international non-profit organisation
aiming to improve health by reducing harm from
misleading drug promotion.23Malaysia
In Malaysia, primary care treatment of the public is pro-
vided by three different types of doctors. These are general
practitioners in private clinics, family medicine doctors who
are undergoing specialist training in teaching hospitals and
family medicine specialists in teaching hospitals or privateclinics. All types of primary care providers were included in
this study.
1. Doctors from family medicine departments in two teach-
ing hospitals in Malaysia, Universiti Sains Malaysia and
Universiti Kebangsaan Malaysia were invited to partici-
pate in this study and asked to nominate two other general
practitioners from private practice.
2. The Malaysian Medical Association (MMA)24 invited its
members to participate in the study.
Overall, 3038 doctors in Australia and 819 doctors in
Malaysia were invited to participate in this study by letter and
email. A reply letter with a prepaid envelope was attached to
the invitation letter. A follow-up letter or email was sent if no
reply was received within two weeks. In Australia, we also
posted a brief advertisement in the newsletter provided by the
South Australia Divisions of General Practice Inc. to invite
doctors to participate in this study. The newsletter was sent to
1738 general practitioners in the division.
An information sheet was sent to doctors who agreed to
participate in the study. Participating doctors were asked to
provide personal details regarding gender, age, years in
practice, postgraduate qualifications, number of doctors in
practice and average number of pharmaceutical representa-
tives they meet with every week. Each doctor was assigned an
identification code.
Pharmaceutical representatives were made aware of the
study and asked for consent to participate. Only doctors
were allowed to obtain written consent from pharmaceutical
representatives.
Questionnaire
After a pharmaceutical representative’s visit, the doctors
filled out a questionnaire focussing on the main product and
claims discussed during the meeting. The majority of the
questionnaire was based on questionnaires developed in
previous studies.25e27 The face validity of the questionnaire
was assessed by six experts in the field of study and doctors
in Australia, Malaysia and Canada. Then, the questionnaire
was modified based on their comments. The questionnaire
focused on the following items (Appendix 1):
Presentation assessment
The doctors were requested to rate the quality and value
of the presentation as well as to provide their opinion on how
convincing the presentation was and whether they would be
more likely to prescribe the presented product.
Responses were further classified as follows:
Quality of presentations: 0e2.5¼ not convincing,>2.5e5
moderately convincing, >5e7.5 convincing, >7.5e10 e very
convincing (convincingness of presentations).
The quality of the information presented: 0e2.5 ¼ poor,
>2.5e5 satisfactory, >5e7.5 good, >7.5e10 outstanding.
Intention to start or increase prescribing: 0e2.5 ¼ No
change, >2.5e5 might change, >5e7.5 change, >7.5e10
intend to prescribe the product more often.
Value of the visit for improving your knowledge: 0e
2.5 ¼ Not useful, >2.5e5 moderately useful, >5e7.5 useful,
>7.5e10 extremely useful.
Table 1: Nature of claims.
Claims Example
Treatment
effectiveness
Effective in treating osteoporosis.
Safety A safe smoking cessation medication
Cost effectiveness It is the most cost effective Angiotensin
Renin Blocker.
Place in therapy Indicated for dementia.
Convenient usage Better compliance as once daily dosage.
Product properties The medicine has the highest ability to
activate receptors at the therapeutic dose.
Table 3: Recruitment and participation of general
practitioners.
General practitioners Australia Malaysia Total
Invited 5046 819 5865
Agreed to participate 41 (1%) 48 (6%) 89 (2%)
General practitioners returned
completed questionnaires
10 (24%) 24 (50%) 34 (38%)
Completed questionnaires
included in the analysis
58 125 183
Number of products discussed 45 84 129
N. Othman et al.474Type of claims
The doctors recorded the main claim made by pharma-
ceutical representatives. The type of claim was classified by a
researcher using the following classifications: effectiveness,
safety, cost effectiveness, place in therapy, convenient usage
and product properties (Table 1). The claims were further
classified as follows: unambiguous, vague, emotive and
non-clinical outcome (Table 2). This classification has been
previously used in two other related studies of the quality
of claims in medical journal advertising.28,29
The doctors were asked to judge whether the claim they
recorded was accurate and to indicate if the word “safe” was
used.
The availability of promotional materials
The doctors were requested to report if any free samples,
gifts or invitations to company-sponsored programmes were
offered.
The doctors were asked to store the completed question-
naires in a secure place and send the questionnaires to the
researchers in a prepaid reply envelope.
Statistical analysis
All of the data were extracted by one researcher. Two
pharmacists from Malaysia independently determined the
nature and type of claims presented by pharmaceutical rep-
resentatives in all of the encounters in both countries. Kappa
tests were conducted with STATA version 10 to assess the
consistency between observers.
The data entry was performed using SPSS database
version 17.0. Descriptive statistics were produced. Chi-
square analysis was used to assess differences in doctors’
views on the sales presentations and quality of claims.Table 2: Types of claims.
Claims Example
A: Unambiguous clinical outcome: When compared with D
faster symptom relief.
B: Vague clinical outcome: DRUG X is a new, effec
of discontinuation due to
C: Emotive or immeasurable outcome: DRUG X e one of a kin
DRUG X e a source of
D: Non-clinical outcome (e.g., drug plasma
half-lives or biochemical markers):
Using DRUG X resulted
luminal diameter in postClustered linear regression was conducted with STATA
10 to assess differences in the doctors’ views of the pre-
sentations of pharmaceutical representatives between doc-
tors in each country. This method allows us to take into
account the fact that each general practitioner met several
pharmaceutical representatives and returned several
completed questionnaires.
Results
A total of 89 general practitioners agreed to participate in
the study, and 34 general practitioners returned 183
completed questionnaires (Table 3). More general
practitioners returned the completed questionnaires in
Malaysia than in Australia. In Malaysia, from 127
returned questionnaires, two were excluded because the
main products discussed were baby milk formula and a
fermented milk drink. In Australia, among the 10 general
practitioners who returned the completed questionnaires,
three were Healthy Skepticism members. On average, each
general practitioner completed six and five questionnaires
in Australia and Malaysia, respectively.
Australian general practitioners were older than Malay-
sian general practitioners (P ¼ 0.01), had more years in
practice (P ¼ 0.02) and were more likely to have post-
graduate qualifications (P ¼ 0.02). Most doctors in both
countries (Australia, 70% (7/10), Malaysia 58% (14/24)) met
between one and three pharmaceutical representatives every
week.
The majority of doctors reported the presentations were
convincing, likely to change theirprescribinghabits andhelped
improve their knowledge (Table 4). The clustered regression
analysis revealed no significant difference between countries
regarding the doctors’ views on the persuasiveness of the
presentation (p ¼ 0.13), quality of information presented
(p ¼ 0.36), likelihood that they would start prescribing theExplanation
RUG X, DRUG Y delivers Clear information on which drugs
were compared to the rate of
symptom relief.
tive pill with a low incidence
skin problems.
How effective? Compare to what?
How low?
d or
healing power.
Immeasurable outcome
in a 30% increase in arterial
-mortem dissections.
Non-clinical information
Table 6: Type of claims.
Classification
of claims
Australia
n/58 (%)
Malaysia
n/165 (%)
P- value
(Comparison Australia
and Malaysia)
Unambiguous 18 (31) 41 (33) P ¼ 0.76
Vague 36 (62) 76 (60)
Emotive 0 2 (2)
Non-clinical 4 (7) 6 (5)
Table 4: Overall presentation assessment (in cm, on a 10-cm
scale).
Assessment Australia
Median
Malaysia
Median
Did you find the representative convincing? 7  1.5 7  1.6
What did you think about the quality of the
information presented?
7  1.3 7  1.4
Did you intend to start or increase
prescribing of the drug?
5  2.9 6  2.8
What did you think about the value of the
visit for improving your knowledge of the
main drug?
6  2.6 7  2.7
Doctors’ views on pharmaceutical representatives’ claims 475products or prescribe them more frequently (p ¼ 0.08) and
value of the visit in terms of the knowledge gained (p ¼ 0.28).
The nature of the claims made in Australia and Malaysia
were not significantly different (Table 5). Approximately half
of the main claims reported by general practitioners in
Australia (57%, 33/58) and Malaysia (50%, 63/125) were
about treatment effectiveness (Table 5). In the majority of
presentations (Australia, 47/58 (81%), Malaysia, 109/125,
88%), general practitioners reported that pharmaceutical
representatives claimed that the promoted medicines were
safe. Among the safety claims made by pharmaceutical
representatives, the majority of claims (Australia 60%, 28/
47, Malaysia 54%, 59/109) indicated that their promoted
medicines were as safe as or safer than a competitor’s
product or placebo including “As safe as any other
angiotensin receptor blockers products” or “The medicine
is safer than other fenofibrate”.
Most doctors (73%, 24/33, p < 0.001) who reported the
intention to prescribe the promoted products viewed the
pharmaceutical representatives as very convincing. Approx-
imately two-thirds of the general practitioners (69%, 35/51,
p < 0.001) who rated the quality of information presented as
outstanding valued the visit as extremely useful for
improving their knowledge of the main drug. No significant
differences were determined for the intention to start or in-
crease prescribing by doctors who reported the presence or
absence of safety information provided by pharmaceutical
representatives (p ¼ 0.91).
The Kappa (k) for the inter-rater reliability between the
researchers on the nature (0.81, z¼ 32.9, p < 0.001) and type
(0.68, z ¼ 19.7, p < 0.001) of claims indicated a substantial
agreement.
Themajority of claims recorded by general practitioners in
Australia and Malaysia were classified as vague claims
(Table 6). Approximately one-third of the claims were un-
ambiguous claims (Australia, 31%18/58), (Malaysia 33%,42/Table 5: Nature of claims.
Classification of claims Australia
n/58 (%)
Malaysia
n/125 (%)
P- value
(Comparison
Australia and
Malaysia)
Treatment effectiveness 33 (57) 63 (50) P ¼ 0.95
Safety 8 (14) 21 (17)
Cost effectiveness 1 (2) 5 (4)
Place in therapy 10 (17) 23 (18)
Convenient usage 2 (3) 5 (4)
Product properties 4 (7) 8 (7)125) (Table 7). In both countries, doctors indicated that most
of the claims that were classified as vague were judged to be
entirely accurate (Australia 31%, 11/31, Malaysia 13%, 10/
76) or mostly accurate (Australia 69%, 25/36, Malaysia
84%, 64/76). The clustered regression analysis found no
significant differences between countries regarding the way
doctors reported the quality of claims (p ¼ 0.34) provided to
them by pharmaceutical representatives.
Healthy Skepticism subscribers (HSS) and non-
subscribers (HNS) reported similar trends in assessing the
quality (p ¼ 0.06) and value of the presentation (p ¼ 0.23),
assessing whether they found the presentation convincing
(p ¼ 0.18) or would be more likely to prescribe the presented
product (p ¼ 0.67) and the accuracy of the claims (p ¼ 0.73).
Most of the general practitioners in both countries
(Australia 69%, Malaysia 63%) reported that they received
samples, gifts or invitation to a company-sponsored program
(Table 9). Promotional brochures were more likely to be
distributed in Malaysia (68%) than in Australia (36%)
(c2 ¼ 16.43; df ¼ 1, P < 0.001). Samples were more likely
to be offered in Australia (41%) than in Malaysia (24%)
(c2 ¼ 5.75; df ¼ 1, P < 0.02). Continuing medical
education was more likely to be offered in Malaysia (70%)
than in Australia (23%) (c2 ¼ 19.61; df ¼ 2, P < 0.001).
In general, the value of the gifts was estimated to be $100
or less in local currency. Forty per cent of Malaysian
doctors who received samples estimated their value to be
between $100 and $500. Nearly a quarter of both
Australian and Malaysian doctors indicated that they
received an invitation to a company-sponsored program
that was valued at $100 to $500.
No significant differences were noted in the physicians’
judgement of how convincing the presentation was
(p ¼ 0.63), the quality of information presented (p ¼ 0.56),
intention to start or increase prescribing (p ¼ 0.09) and the
value of the visit for improving knowledge (p ¼ 0.12) perti-
nent to the presence or absence of offered gifts.
Discussion
General practitioners in Australia and Malaysia typically
held positive views of the presentation of pharmaceutical
representatives. These practitioners rated the presentations
as moderate and moderately high in terms of the persua-
siveness of the presentation, the quality of information pre-
sented, the likelihood that they would start prescribing the
pharmaceutical representatives’ products or prescribe them
more frequently and the value of the visit in terms of
knowledge gained. These positive views are consistent with
the results from previous studies, which were conducted in
the US,7,9 Peru30 and the UK.8
Table 7: Doctors’ responses to claims by various pharmaceutical representatives.
Variables Australia
n/58 (%)
Malaysia
n/125 (%)
P- value
(Comparison Australia and Malaysia)
Did you feel the main claim was accurate? Entirely accurate 19 (33) 14 (11) P ¼ 0.01
Mostly accurate 38 (65) 105 (84)
Entirely inaccurate 0 2 (2)
Mostly inaccurate 1 (2) 4 (3)
Representatives claim that the product was safe Yes 47 (81) 109 (88) P ¼ 0.27
No 11 (19) 16 (13)
Doctors’ responses to claims by various pharmaceutical representatives.
Table 8: Some examples of marketing claims.
Claims Nature Type Reason Doctors’ judgement Country
“ Longer half-life than other
angiotensin receptor blocker”
Product properties Non-clinical Pharmacokinetics information Mostly accurate Malaysia
“Reduce incidence of MI in post
infarct and stroke patients”
Treatment
effectiveness
Vague How good? Mostly accurate Australia
“Powerful BP reduction in a
combined fixed dose tablet”
Treatment
effectiveness
Emotional “Powerful” e Immeasurable
outcome
Mostly accurate Malaysia
“Superior than Viagra” Treatment
effectiveness
Emotional “Superior” e Immeasurable
outcome
Mostly accurate Malaysia
“No weight gain with its use” Safety Unambiguous Clear explanation on the safety
profile
Mostly accurate Australia
“Indicated in anxiety-depression” Place in therapy Unambiguous Clear explanation on indication Mostly accurate Malaysia
“Effective in treating osteoporosis” Treatment
effectiveness
Vague How effective? Entirely accurate Australia
“Less side effects” Safety Vague Compare to which medicines?
How safe?
Mostly accurate Malaysia
Table 9: Promotional materials.
Promotional materials Australia
n/58 (%)
Malaysia
n/125
(%)
P- value
(Comparison Australia
and Malaysia)
Did the representative give you any promotional
brochures?
Yes 21 (36) 85 (68) P < 0.001
No 37 (64) 40(32)
Did the representative give you any samples? Yes 24 (41) 30 (24) P ¼ 0.02
No 34 (59) 95 (76)
If yes, what is the estimated value? <$100 22/24 (92) 17/30 (57) P ¼ 0.002
$100e500 2/24(8) 12/30 (40)
>$500 0 1/30 (3)
Did the representative give you any gifts Yes 18 (31) 52 (42) P ¼ 0.17
No 40 (69) 73 (58)
If yes, please specify (e.g., pen, notepad, etc.) Pens 9/18 (50) 38/52 (73) P ¼ 0.04
Notepads 2/18 (11) 13/52 (25)
Others (Pillow, ruler,
calendar, planner,
bag, knife)
10/18 (56) 12/52 (23)
What is the estimated value of the gifts? <$100 17/18 (94) 52/52 (100) P ¼ 0.09
$100e500 1/18 (6) 0
> $500 0 0
Did you receive any invitation to a company-sponsored
program? (e.g., medical education program, dinner,
conferences, symposiums and research trials).
Yes 13 (22) 30 (24) P ¼ 0.81
No 45 (78) 95 (76)
If yes, please specify Free lunch or dinner 10/13 (77) 3/30 (10) P < 0.001
CME 3/13 (23) 21/30 (70)
Conference 0 6/30 (20)
What is the estimated value? <$100 10/13 (77) 18/30 (60) P ¼ 0.28
$100e500 3/13(23) 7/30 (23)
>$500 0 5/30 (17)
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Doctors’ views on pharmaceutical representatives’ claims 477The doctors’ views regarding the educational value of the
information given by pharmaceutical representatives are in
contrast with research indicating that pharmaceutical repre-
sentative presentations often provide incomplete informa-
tion.27,31 However, in addition to providing information,
pharmaceutical representatives can employ a range of
persuasive techniques that aim to influence doctors’ opinions,
such as appeals to authority figures, social validation acts
and reciprocity acts through the provision of gifts.32 In our
study, approximately two-thirds of general practitioners in
Australia (69%) and Malaysia (63%) indicated that they
received samples, gifts or invitations to a company-sponsored
program. This result is consistent with the results from other
studies.27,33 In a 2005 survey, most Australian specialists
reported that they received food (90%), items for the office
(90%), personal gifts (57%) and invitation to product
launches, symposia or educational events (75e84%).33 The
provision of gifts may create indebtedness17 that may result
in inappropriate changes in prescribing drugs.34,35 Although
both the Australian and Malaysian code of conduct only
permit the distribution of small gifts in the form of
promotional aids, research has shown that even small gifts
can have a negative effect on the prescribing behaviour of
health professionals.36 The results from a recent US study
indicated that subtle exposure to small pharmaceutical
promotional items influences attitudes toward marketed
products among medical students.37 Therefore, several
professional organisations in several countries including the
Royal Australasian College of Physician’s in Australia38 and
the Wisconsin State Medical Society39 in the US have
adopted guidelines that prohibit the acceptance of gifts.
Samples were frequently given to doctors in Australia
(41%) and Malaysia (24%). The provision of samples has
been questioned because it may raise health care costs by
promoting the use of new and expensive brand products.14 In
addition, samples being given to patients based on
inadequate information may increase the risk of adverse
drug reactions.43e45 Although this result was based on a
small sample size, it provides researchers with preliminary
comparative data for future research that has potential
important implications for the success of generic policies
that were adopted by both Australia and Malaysia.41,42
Most of the claims recorded by general practitioners in
Australia (62%) andMalaysia (60%) were classified as vague
claims. Vague claims do not provide complete information
based on measureable outcomes (e.g., “Better efficacy”,
“Effective”- without quantification). The insufficient infor-
mation on the medicines provided in vague claims is unlikely
to support doctors in making appropriate prescription de-
cisions. This result adds to the body of evidence suggesting
that most claims presented in pharmaceutical promotions are
vague.28,29
In both countries, doctors indicated that most of the
vague claims regarding benefits or harms were accurate
(Australia 31%, Malaysia 13%) or mostly accurate
(Australia 69%, Malaysia 84%).
This result suggests that doctors believed in the accuracy
of claims despite most of the claims being classified as vague.
Vague claims do not provide comprehensive medical infor-
mation that allows doctors to judge the accuracy of claims.
The doctors are susceptible to misinterpreting the accuracy
of information provided by pharmaceutical representatives.In addition, these doctors are less likely to support the
quality use of medicines when their prescribing practices
were based on vague claims (Table 8).
Doctors may lack critical skills to objectively assess the
quality of information provided in pharmaceutical pro-
motions. This concern regarding critical appraisal skills has
led to several initiatives to train doctors in analysing infor-
mation on medicines.40,41 The World Health Organization
(WHO) and Health Action International (HAI) have
collaborated to produce a manual that provides practical
training for medical and pharmacy students to recognise a
variety of promotional techniques.40 The US Food and
Drug Administration (FDA) introduced a “Bad Ad
Program” that educates health care professionals to
recognise misleading or inaccurate promotions and report
them to the agency.41 These programs are essential to
encourage health professionals to be sceptical about medical
information provided by commercial sources. Our results
also highlight the need for doctors to rely more on non-
commercial sources of information. The doctors in
Australia have access to comprehensive independent sources
of information onmedicines, such as theNational Prescribing
Services,42 The Australian Medicines Handbook43 and
Therapeutics Guidelines.44 However, in Malaysia, limited
independent information is available.45 The Malaysian
government should consider developing suitable and
effective services to provide independent information on
medicines to health professionals.
This study is an exploratory study. The small sample size
and non-random sampling in this study limit the external
validity of the study, and the results cannot be generalised to
all Australian and Malaysian doctors. In addition, only
general practitioners with an active interest in issues related
to pharmaceutical promotions were more likely to partici-
pate. The scale used in our questionnaire on the doctors’
opinion on the accuracy of the main claim included ‘entirely’
or ‘mostly’ accurate or ‘entirely’ or ‘mostly’ inaccurate. The
scale did not enable doctors to consider middle values to be
selected. Doctors might respond differently if a visual
analogue scale was used.
Another limitation is that our results are based on self-
reporting by general practitioners, which may be subject to
recall bias. However, the surveys were completed immedi-
ately after the encounter. Therefore, the recall bias was likely
to be limited. Because the claims were reported by doctors
and classified by researchers, an overestimation of vague
claims may have occurred.
Conclusion
Doctors in Australia and Malaysia typically held positive
views of pharmaceutical representative presentations. Most
claims were classified as vague. Because most doctors
received samples, gifts or invitations to company-sponsored
programs, they need to be aware of the potential conse-
quences of the quality use of medicines.Conflict of interest
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